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Abstract
Statistical methodology for the design and analysis of clinical Phase II dose response studies,
with related software implementation, are well developed for the case of a normally distributed,
homoscedastic response considered for a single timepoint in parallel group study designs. In
practice, however, binary, count, or time-to-event endpoints are often used, typically measured
repeatedly over time and sometimes in more complex settings like crossover study designs. In
this paper we develop an overarching methodology to perform efficient multiple comparisons
and modeling for dose finding, under uncertainty about the dose-response shape, using general
parametric models. The framework described here is quite general and covers dose finding using
generalized non-linear models, linear and non-linear mixed effects models, Cox proportional
hazards (PH) models, etc. In addition to the core framework, we also develop a general
purpose methodology to fit dose response data in a computationally and statistically efficient
way. Several examples, using a variety of different statistical models, illustrate the breadth of
applicability of the results. For the analyses we developed the R add-on package DoseFinding,
which provides a convenient interface to the general approach adopted here.
1Janssen Research & Development, Raritan, NJ, 08869, USA.
2Novartis Pharma AG, CH-4002 Basel, Switzerland.
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1 Introduction
Finding the right dose is a critical step in pharmaceutical drug development. The problem of
selecting the right dose or dose range occurs at almost every stage throughout the process of
developing a new drug, such as in microarray studies [25], in-vitro toxicological assays [8], animal
carcinogenicity studies [18], Phase I studies to estimate the maximum tolerated dose [26], Phase
II studies covering dose ranging and dose-exposure-response modeling [20], Phase III studies for
confirmatory dose selection, and post-marketing studies to further explore dose response in specific
subgroups defined by region, age, disease severity and other covariates [31, 32, 22]. In recent years,
considerable effort has been spent on improving the efficiency of dose finding throughout drug
development [37, 12, 24]. Despite these efforts, however, improper dose selection for confirmatory
studies, due to lack of sufficient dose response knowledge for both efficacy and safety at the end of
Phase II, remains a key driver of the ongoing pipeline problem experienced by the pharmaceutical
industry [5, 28].
Statistical analysis methods for late development dose finding studies can be roughly categorized
into modelling approaches to characterize the dose response relationship [30, 36] and multiple test
procedures for dose response signal detection [34] or confirmatory dose selection [35, 9]. Hybrid
approaches combine aspects of multiple testing with modeling techniques to overcome the short-
comings of either approach [38, 10]. More recently, considerable research has focused on extending
these methods to response-adaptive designs that offer efficient ways to learn about the dose response
through repeated looks at the data during an ongoing study [16, 15, 23, 4].
Most statistical methodology for dose response analysis has been introduced in the context of a
normally distributed, homoscedastic endpoint, with a parallel group design, in which each patient
receives only one treatment. In practice, however, one often faces more complex study designs
(e.g., cross-over designs), where a heteroscedastic or non-normally distributed endpoint is measured
(e.g., binary, count and sometimes time-to-event data). One approach is to extend the existing
methodology using generalized non-linear models or generalized non-linear mixed effects models.
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However, these extensions are typically specific to each new situation. In addition general purpose
software for these types of models is not available and a case-by-case implementation requires a
major coding effort. In this paper, we describe an overarching hybrid approach, combing multiple
comparisons and modeling, to the analysis of dose response data for general parametric models and
general study designs, that allows for a straightforward computer implementation.
Figure 1: Overview of MCPMod approach
More specifically, we extend the MCPMod approach [10], which was originally introduced for nor-
mal, homoscedastic, independent data. This approach provides the flexibility of modeling for dose
response and target dose estimation, while accounting for model uncertainty through the use of
multiple comparison and model selection/averaging procedures. The approach can be described in
two main steps (Fig. 1). At the trial design stage the clinical team needs to decide on the core
aspects of the trial design, as in any other trial. Specific for MCPMod is that a candidate set of
plausible dose response models is pre-specified at this stage, based on available pharmacokinetic
data/dose response information from similar compounds, etc. This gives rise to a set of optimal
contrasts used to test for the presence of a dose response signal consistent with the corresponding
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candidate models. In case of large model uncertainty, this candidate set should be chosen to cover
a sufficiently diverse set of plausible dose response shapes
The trial analysis stage consists of two main steps: The MCP and the Mod steps. The MCP
step focuses on establishing evidence of a drug effect across the doses, i.e., detecting a statistically
significant dose response signal for the clinical endpoint and patient population investigated in the
study. This step will typically be performed using an efficient test for trend, adjusting for the fact
that multiple candidate dose response models are being considered. If a statistically significant
dose response signal is established, one proceeds with determining a reference set of significant dose
response models by discarding the non-significant models from the initial candidate set. Out of this
reference set, a best model is selected for dose estimation in the last stage of the procedure, using
existing non-linear regression methods [2]. The selected dose-response model is then employed to
estimate target doses using inverse regression techniques and possibly incorporating information on
clinically relevant effects. The precision of the estimated doses can be assessed using, for example,
bootstrap methods.
The original MCPMod method proposed by [10] was intended to be used with parallel group designs
with a normally distributed, homocedastic response. Although that covers a good range of dose
finding designs utilized in practice, the restrictions of the original method create serious practical
limitations to its wider use in drug development. For example, binary, count, and time-to-event
endpoints, though frequently used in many disease indications, are not covered by the original
MCPMod formulation. Likewise, longitudinal patient data, like in crossover studies, with its im-
plicit within-patient correlation, cannot be properly analyzed with the original formulation of the
MCPMod methodology. In what follows, we extend the MCPMod methodology, to perform dose
response modeling and testing in the context of general parametric models and for general study
designs, in a similar way as [19] extended certain simultaneous inference procedures. Note that,
even though we focus on extending the MCPMod approach, the results of this paper remain valid,
in particular, if only a multiple comparison or a modeling approach is to be applied.
We introduce the proposed extension in Section 2. In Section 3 we describe an efficient approach
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for dose response model fitting, which is evaluated in terms of asymptotic considerations and sim-
ulations. In Section 4 we use several case studies to illustrate the proposed methodology and its
implementation with the R add-on package DoseFinding [6]. In summary the method is illustrated
for binary, overdispersed count, time-to-event data (based on the Cox PH model) and longitudinal
data with patient specific random effects.
2 Generalized MCPMod
This section describes an extension of the original MCPMod approach that can be used whenever
the response variable can be described by a parametric model in which one of the parameters
captures the dose response relationship. We show how the basic ideas and concepts of the original
MCPMod can be extended to this setting.
2.1 Basic concepts, notation and assumptions
In the original description of MCPMod, the expected value of the response is utilized as the parame-
ter capturing the dose response relationship. The key idea of the extended version of MCPMod is to
decouple the dose response model from the expected response, focusing, instead, on a more general
characterization of dose response via some appropriate parameter in the probability distribution of
the response. To be more concrete, let y denote the response vector of an experimental unit in the
trial (e.g., a patient) which has been assigned a dose x. The following results can easily be extended
to the case of multiple doses x, if needed. We assume that y follows the distribution function given
by
y ∼ F (z,η, µ(x)) , (1)
where µ(x) denotes the dose response parameter, η the vector of nuisance parameters, and z
the vector of possible covariates. The key features of extended version of MCPMod can then be
formulated with respect to µ(x), such as:
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• accounting for uncertainty in the dose response model via a set of candidate dose response
models,
• testing of dose response signal via contrasts based on dose response shapes,
• model selection via information criteria, or model averaging to combine different models, and
• dose response estimation and dose selection via modeling.
Because all dose response information is assumed to be captured by µ(x), the interpretability of
this parameter is critical for communicating with clinical teams, choosing candidate dose response
shapes, specifying clinically relevant effects for target dose estimation, etc. To better illustrate this
point, consider a time-to-event endpoint that is assumed to follow a Weibull distribution. The
Weibull distribution is typically parameterized by a scale parameter λ and shape parameter α,
neither of which has an easy clinical interpretation. For the purpose of MCPMod modelling the
model could be reparameterized in terms of the median time to event µ = [log(2)]1/α /λ and α, and
then one would use µ(x) as an interpretable dose response parameter.
All dose response models of interest in this paper can be expressed as
f(x, θ) = θ0 + θ1f
0(x, θ0), (2)
where f 0 denotes the so-called standardized model function and θ0 its parameter vector. For
example, for f 0(x, θ0) = x one obtains the linear model f(x, θ) = θ0 + θ1x and for f
0(x, θ0) =
x/(x+θ0) the Emax dose response model f(x, θ) = θ0+θ1x/(x+θ
0); see [10, 7] for more examples.
Dose response models of the form (2) are specified as candidate models for µ(x). Covariates may
also be included in (2), at the model fitting stage, but we leave them out for now to keep the
notation simple.
Assume that K distinct doses x1, . . . , xK are utilized in a trial, with x1 denoting placebo. Assume
further that M candidate models f1, . . . , fM have been chosen to capture the model uncertainty
about µ(x). We define the dose response parameter vector associated to candidate model m as
µm = (µm,1, . . . , µm,K) , where µm,i = fm(xi, θ), i = 1, . . . , K,m = 1, . . . ,M .
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For the purpose of obtaining estimates of the dose response, we initially consider an analysis-of-
variance (ANOVA) parametrization for the dose response parameter µ(xi) = µi, i = 1, . . . , K.
That is, we allow a separate parameter µi to represent the dose response at each dose level. Let µ̂
denote the vector of estimated dose response parameters under the ANOVA parametrization, ob-
tained using the appropriate estimation method for the general parametric model (1) via maximum
likelihood (ML), generalized estimating equations (GEE), partial likelihood, etc. Note that these
type of ANOVA estimates are easily available from standard statistical software packages. The key
assumption underpinning the extended version of MCPMod is that µ̂ has an approximate distri-
bution N (µ,S) , where S denotes the variance-covariance of µ̂. This assumption can be shown
to hold for most parametric estimation problems, such as, generalized linear models, parametric
time-to-event models, mixed-effects models, GEE, etc. Note that S is a function of n and converges
to 0 as n → ∞. Furthermore, S may or may not depend on x. For example, dependence on x
arises if unequal variances for different dose levels xi are considered. The estimation of θ is done in
a separate second stage based on µ̂ and an estimate Ŝ of its covariance matrix. Section 3 explains
this in detail.
2.2 Implementation of the MCP step
The MCP step consists of specifying a set of candidate models for the dose response relationship
µ(x). To that end, one needs to specify families of candidate models (e.g., linear, Emax, logistic,
quadratic). In addition, to derive optimal model contrasts, one needs to determine guesstimates
for the non-linear parameters θ0, such as the ED50 parameter for the Emax model. Note that the
shape of the dose response model function is determined by the parameter θ0, which is why only
guesstimates for this parameter are needed to derive optimal model contrasts. As mentioned earlier,
the clinical interpretability of µ(x) is critical for this step. Further details on and strategies for the
specification of candidate models and corresponding guesstimates are given in [29].
Given these guesstimates, each candidate model shape determines an optimal contrast for a trend
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test to evaluate the associated dose response model signal, such as a linear trend or a trend based
on an Emax model with ED50 = 2. The optimal contrasts are applied to the previously described
ANOVA estimates µ̂, with the associated asymptotic distribution used for implementing the cor-
responding tests (i.e., critical values and p-values). It can be shown that the (optimal) contrast
for testing the hypothesis of a flat dose-response profile with maximal power for a single candidate
model shape µm is given by
copt ∝ S−1
(
µ0m −
µ0′mS
−11
1′S−11
)
, (3)
where µ0m = (f
0
m(x1, θ
0), . . . , f 0m(xK , θ
0))′ and θ0 is the parameter for which guesstimates are re-
quired, see [10] and Appendix A. For convenience, we normalize the contrast coefficients such that
||copt|| = 1.
The implementation of contrast tests for the candidate models is done similarly to the original
MCPMod approach. Let copt1 , . . . , c
opt
M represent the optimal contrasts corresponding to the set
of candidate models and Copt =
[
c
opt
1 · · · coptM
]
the associated optimal contrast matrix. The con-
trast estimates are then given by
(
Copt
)′
µ̂, being asymptotically normally distributed with mean(
Copt
)′
µ and covariance matrix
(
Copt
)′
SCopt. It follows that the asymptotic z-test statistic for
the mth candidate model hypotheses H0 : (c
opt
m )
′
µ = 0 vs. H0 : (c
opt
m )
′
µ > 0 is given by
zm = (c
opt
m )
′
µ̂/
[(
Copt
)′
SCopt
]1/2
m,m
, with [A]m,m denoting the m
th diagonal element of the ma-
trix A. The test statistic used for establishing an overall dose response signal is the maximum
z(M) = maxm zm of the individual model test statistics. Critical values for tests with (asymptoti-
cally) exact level α can be derived from the joint distribution of z = (z1, . . . , zM), which is easily
obtained from the joint distribution of the contrast estimates given previously, and using
P (z(M) > q) = 1− P (z(M) ≤ q) = 1− P (z ≤ q1). (4)
Multiplicity adjusted p-values for the individual model contrast tests can be derived similarly. The
mvtnorm package in R includes functions to calculate quantiles and probabilities for the underlying
multivariate normal distributions [17].
If the optimal contrasts and the critical values also depend on S, one needs guesstimates for nuisance
parameters appearing in the covariance matrix at the planning stage, as well. This is a difference
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compared to the normal homoscedastic setting without covariates, where S is proportional to a
diagonal matrix with the the reciprocal of the group sample sizes on the diagonal. Once data
becomes available, the z-statistics for the model contrast tests are calculated and their maximum
used for the dose response test. At this stage, one can obtain the estimated Ŝ matrix from the
observed data, and use this to recalculate optimal contrasts and the critical value for the test. Note
that the guesstimates for the parameters θ0 are not recalculated based on the observed data, as
this would lead to a serious Type I error rate inflation. For the purpose of the multiple contrast
test, the guesstimates pre-specified at the planning stage for θ0 should be used.
2.3 Implementation of the Mod step
Once a dose response signal is established, one proceeds to the Mod step, fitting the dose response
profile and estimating target doses based on the models identified in the MCP step. There are
many ways to fit the dose response models to the observed data, including approaches based on
maximizing the likelihood (ML) or the restricted likelihood. However, a direct ML approach requires
the derivation of the likelihood in every specific case, with a considerable amount of model-specific
coding involved. We therefore suggest an alternative two-stage approach to dose response model
fitting that utilizes generalized least squares. This approach is described in more detail in Section 3.
It relies on asymptotic results, but has the appeal of being of general purpose application, as it
depends only on µ̂ and Ŝ. In addition, as shown later in the simulation study, its finite and large
sample properties are similar to those of the approaches based on the full likelihood.
Model selection can be based on the maximum z-statistics, or using information criteria, such as
the AIC or the BIC. Estimates of the latter under the model fitting approach are discussed in the
next section. Estimation of target doses is done based on the selected fitted model for the dose
response parameter [7].
Alternatively, model averaging approaches can be used to avoid the need to select a single model.
The individual AIC and BIC values for the candidate models with significant contrast test statistics
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determine the model averaging weights [11]. This applies both to dose response and target dose
estimation.
The generalization of MCPMod described in this section has focused on testing and estimation
associated with the full dose response profile, that is, including the response at placebo and the
entire dose range utilized in the study. In practice, there are cases in which inference might focus
on the placebo-adjusted dose response (or more generally a control-adjusted response), that is,
the dose response with the placebo or control effect subtracted fC(x, θ) = f(x, θ) − f(0, θ). This
could become relevant, for example, if covariates are added to the placebo response θ0 in (2). In
the context of time-to-event data, the focus on placebo-adjusted dose response will occur naturally
when modeling the hazard ratio as a function of dose. As shown in Appendix B, all results presented
in this section, including the derivation of optimal contrasts, as well as the model fitting results
described in the next section, apply equally in the context of placebo-adjusted dose response.
3 Non-linear dose response model fitting using a two-stage,
generalized least squares approach
In this section we describe an efficient methodology for fitting nonlinear dose response models that
can be used for the Mod step of the MCPMod methodology. The fitting is done in two stages:
First, the ANOVA estimates µ̂ and Ŝ introduced in Section 2 are obtained. Second, the parameter
θ is estimated by fitting the dose response model to the ANOVA estimates from the first step
using a generalized least squares estimation criterion. In Section 3.1, we establish consistency and
asymptotic normality of this estimate. In Section 3.2 we assess the accuracy of the asymptotic
results via a simulation study.
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3.1 Asymptotic results
Assume that we have dose response estimates µ̂ = (µ̂1, . . . , µ̂K)
′ obtained from an ANOVA-type
parameterization of µ which allows for unrelated mean responses at each of the K dose levels; see
Section 2.1. These estimates are assumed to be asymptotically multivariate normal distributed with
a covariance matrix consistently estimated by Ŝ. The estimates µ̂ and Ŝ are easily available from
standard statistical packages, see Section 4 for examples using R. Next, we fit the non-linear dose
response model f(x, θ) to the estimates µ̂ by minimizing the generalized least squares criterion
Ψ̂(θ) = (µ̂− f (x, θ))′An(µ̂− f (x, θ)) (5)
with respect to θ to obtain the estimates θ̂. In Equation (5) we have f(x, θ) = (f(x1, θ), . . . , f(xK , θ))
′
and An denotes a symmetric positive definite matrix. We assume that An
P→ A, where P→ denotes
convergence in probability. In practice we will always use An = Ŝ
−1
, but this would unnecessarily
restrict the discussion at this stage.
Let θ0 denote the true value of the parameter θ. In Appendix C we show that, under mild regularity
conditions, θ̂ is a consistent estimator of θ0, i.e., θ̂
P→ θ0. Furthermore, we have the asymptotic
multivariate normality
√
an(θ̂ − θ0) d→ N(0,B(θ0)′M(θ0)B(θ0)), (6)
where M (θ) = anF (θ)
′ASAF (θ) and B(θ) = (F (θ)′AF (θ))−1, F (θ) denotes the d × k matrix
of partial derivatives df(xi,θ)
dθh
(i = 1, ..., k, h = 1, ..., d), an a non-decreasing sequence of values
increasing to infinity as the sample size n goes to infinity.
Selecting An = S
−1 would be the best choice, if S were known. Provided that anS
P→ Σ as n→∞,
the previous formulas in this case simplify to
√
an(θ̂ − θ0) d→ N(0, (F (θ0)Σ−1F (θ0)′)−1) with θ̂
minimizing
Ψ̂(θ) = (µ̂− f(x, θ))′S−1(µ̂− f (x, θ)) (7)
with respect to θ. Because S is not known, we will typically use a consistent estimate Ŝ of it in (7).
If the assumptions about the covariance matrix are wrong in the sense that anŜ does not converge
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to Σ, then θ̂ will still be consistent and have the asymptotic normal distribution given in (6). In
this regard, the suggested estimator is similar to Huber’s robust estimator ([21]; Section 4.6 in [13]),
but this aspect will not be further utilized.
Note that this two-stage, generalized least squares estimate is quite similar to the ML estimate: For
normal homoscedastic data both approaches lead to exactly the same estimate, while, for example,
in generalized linear model settings the two estimators have the same large-sample variance; see
Chapter 4.3 in [14].
The computational advantage of using this two-stage approach is that the target function in (7)
that is optimized numerically is low-dimensional: The dimension is equal to the number of different
dose levels and the target function can thus be evaluated quite efficiently, while the target function
in a full likelihood approach depends on the complete data set. This difference in speed becomes
relevant in clinical trial settings, as often extensive clinical trial simulations are used to evaluate
proposed study designs. Another advantage of the proposed method is its broad applicability to
general parametric models.
Model selection criteria are generally defined as −2 log(L) + dim(θ)τ , where L denotes the likeli-
hood function evaluated at the maximum likelihood estimate and τ a penalty for the number of
parameters, which depends on the model selection criterion. One approach to model selection is
hence to use Ψ̂(θ̂) + dim(θ)τ to compare different dose response models fitted based on the same
µ̂ and S. This criterion is motivated by the fact that, for normally distributed homoscedastic data
without covariates, these two approaches are equivalent in terms of selecting the same model: The
likelihood function can be split into the sum of the deviation between the observed data and µ̂ and
the deviation between µ̂ and f (x, θ̂). The deviation of the individual data and µ̂ is identical across
the different dose response models, so that the criterion only varies with the deviation between µ̂
and f (x, θ̂), which, in case of normal data, is equal to Ψ̂(θ̂). In situations beyond the normal
case both approaches might lead to slightly different results, however as (7) is roughly proportional
to −2·log-likelihood of the ML estimate of θ, when discarding the contribution of the first stage
ANOVA-type fit (which is equal for all dose response models considered) typically both approaches
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will lead to very similar results. Subsequently τ = 2 will be used and we refer to this criterion as
gAIC.
In the next subsection we investigate the properties of the proposed asymptotic approximations via
simulations before illustrating it with several applications in Section 4.
3.2 Simulations
In this section we evaluate the asymptotic performance of the approximations provided in Section
3.1 for fitting a single nonlinear dose response model. More specifically, we compare the proposed
methods with more traditional maximum likelihood estimation by evaluating the dose response
estimation accuracy using simulations. In addition we assess the coverage probability of the resulting
confidence intervals for the model parameter θ.
3.2.1 Design of simulation study
Throughout the simulations we assume five active dose levels 0.05, 0.2, 0.5, 0.8, 1 plus placebo. We
investigate equal group sample sizes of 15, 30, 50, 100, 300 and 1000 patients for each dose. The
lower range of the investigated sample sizes is realistic for typical Phase II dose response studies,
while the sample sizes of 300 and 1000 are included to assess the asymptotic behavior.
We investigate three types of data: binary data, overdispersed count data using a negative binomial
model and time-to-event data using a Cox PH model for estimation. Regarding dose response
models, we will utilize an Emax model µ(x, θ) = θ0 + θ1x/(θ2 + x), a quadratic model µ(x, θ) =
θ0 + θ1x + θ2x
2 and an exponential model µ(x, θ) = θ0 + θ1(exp(x/θ2) − 1). In the simulations,
we set θ2 = 0.05 for the Emax model, θ2 = 0.2 for the exponential model and θ1/θ2 = −5/8 for
the quadratic model; see Figure 2 for the underlying model shapes. The remaining parameters θ0
and θ1 are chosen such that the power for testing the dose with the maximum treatment effect
against placebo at the 5% one-sided significance level is 80% for 30 patients per group. This
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Figure 2: Dose Response Models used for simulation
ensures a realistic range of sample sizes (in terms of the signal to noise ratio) is investigated in the
simulations.
Data type Quadratic Emax Exponential
binary (−1.734, 4.335,−2.7094) (−1.734, 1.8207, 0.05) (−1.734, 0.01176, 0.2)
count (2,−2, 1.25) (2,−0.84, 0.05) (2,−0.005427, 0.2)
time-to-event (0,−1.8876, 1.1797) (0,−0.7928, 0.05) (0,−0.005122, 0.2)
normal (0, 2.61, 1.633) (0, 1.097, 0.05) (0, 0.007089, 0.2)
Table 1: Dose Response Model Parameters (θ0, θ1, θ2) used for simulation
Table 1 summarizes the three dose response model specifications for each data type. For binary
data, Table 1 gives the the mean on the logit scale. For count data, the logarithm of the mean
is as specified in Table 1 and the overdispersion parameter is 1. For time-to-event data, we use
an exponential distribution for data generation with the log-means specified in Table 1 and where
observations larger than 10 are censored. The mean in the placebo group is 1, so that the log-mean
is equal to the difference in log-hazard rates. The Cox PH model is formulated relative to the control
group, so that, in this case, the placebo parameter is set to 0 when estimating the dose response
model. In addition, we include normally distributed data with σ = 1 as a benchmark comparison,
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since in this case the two-stage, generalized least squares (GLS) and ML estimates coincide.
We use the two-stage approach from Section 2 to obtain (i) an ANOVA-type model fit to the data
by using either a generalized linear model (binary and count data) or a Cox PH model (time-to-
event data) with “dose” treated as a factor and (ii) a dose response model fit to the resulting dose
response estimates obtained via generalized least squares (7), together with the asymptotic results
from Section 3.1. In the simulations, we compare this approach to nonlinear maximum likelihood
(binary and count data) and maximum partial likelihood (time-to-event data) estimation using the
same link functions as above. For the model fitting step, we assume lower and upper bounds for the
θ2 parameter of 0.001 and 5 for the Emax and 0.05 and 5 for the exponential dose response model.
In addition, we assess the coverage probability for three different methods of constructing confidence
intervals for the dose response model parameter θ. First, we use the generalized least squares (7)
together with the asymptotic results from Section 3.1 (denoted below as GLS). Second, we use
parametric bootstrap confidence intervals by sampling from the multivariate normal distribution
underlying the first stage ANOVA-type estimates and then fitting the nonlinear model to each
of these samples using the GLS criterion from (7). The bootstrap confidence intervals are then
calculated by taking the 5% and 95% quantiles of the observed sample. For each simulation we
used 500 bootstrap samples (denoted below as GLS-B). Finally, we use the maximum likelihood
fits and calculate confidence intervals based on the inverse of the Hessian matrix and the usual
asymptotic normality assumptions (denoted below as ML).
3.2.2 Results of simulation study
Simulations were run with 2000 replications, using the DoseFinding package version 0.9-1. To
illustrate the performance of the GLS and ML methods with regard to dose response estima-
tion, we calculated the root mean squared estimation error averaged over the available doses√
1
6
∑
x∈D
(f(x, θ̂)− f(x, θ))2, where D = {0, 0.05, 0.2, 0.6, 0.8, 1}. Figures 9, 10 and 11 in the Ap-
pendix display the results. It is evident from these plots that both approaches can hardly be distin-
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guished in terms of the mean squared error, indicating that, in terms of dose response estimation,
both methods perform almost identically, even for small sample sizes.
Next, we assess the coverage probability for the three different methods described at the end of
Section 3.2.1. Figure 3 displays the results only for the count data case, because the results for the
binary and time-to-event data are nearly indentical. We observe that the asymptotic confidence
intervals for the GLS and ML methods perform very similarly for all three models under investigation
(Emax, exponential, quadratic). Both methods achieve the nominal 90% coverage probability fairly
well for the quadratic model, even for small sample sizes. For the Emax model, the nominal coverage
probability is achieved at roughly 50-100 patients per group, whereas for the exponential model the
coverage probability is achieved only at very large sample sizes (the poor performance of standard
asymptotic confidence intervals for nonlinear regression models even for moderate sample sizes is
well-known, see for example, [27]). The reason for the better performance under the quadratic
model is the fact that it is linear in the model parameters. One reason for why the confidence
intervals perform worse for the exponential model than for the Emax model might be that the dose
design used in the simulations allows an easier identification of the model parameters under the
Emax model, because there are more dose levels in the lower part of the dose range than the upper
part.
In contrast, the parametric bootstrap approach GLS-B achieves the 90% nominal coverage prob-
ability fairly well for all three dose response models, even at sample sizes as small as 30 patients
per group. The GLS-B method thus performs always at least as well as the GLS and ML methods,
and the general recommendation is to use this in case of small sample sizes. The approach is com-
putationally more expensive, as it requires repeated fitting of the dose response models, but the
bootstrap-based on the GLS two-stage fitting is computionally much more efficient than a traditional
bootstrap approach based on ML: The GLS two-stage approach only depends on the ANOVA type
estimates and not the individual observations, which makes evaluation of Ψ̂(θ̂) computationally
much cheaper than evaluation of the full likelihood function.
In summary, we conclude that both the GLS and ML methods perform similarly under the different
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dose response shapes, sample sizes, and data types investigated in the simulation study. This
conclusion holds both for the coverage probabilities, as well as for the average estimation error. As
mentioned previously, however, the GLS method is very general and computationally more efficient,
which facilitates the usage of computationally expensive techniques such as the bootstrap approach.
4 Applications
4.1 Longitudinal modeling of neurodegenerative disease
This example refers to a Phase 2 clinical study of a new drug for a neurodegenerative disease. The
state of the disease is measured through a functional scale, with smaller values corresponding to
more severe neurodeterioration. The goal of the drug is to reduce the rate of disease progression,
which is measured by the linear slope of the functional scale over time.
The trial design includes placebo and four doses: 1, 3, 10, and 30 mg, with balanced allocation of
50 patients per arm. Patients are followed up for one year, with measurements of the functional
scale being taken at baseline and every three months thereafter. The study goals are to (i) test the
dose-response signal, (ii) estimate the dose-response and (iii) select a dose to be brought into the
confirmatory stage of the development program.
The functional scale response is assumed to be normally distributed and, based on historical data,
it is believed that the longitudinal progression of the functional scale over the one year of follow
up can be modeled by a simple linear trend. We use this example to illustrate the application of
MCPMod in the context of mixed-effects models.
We consider a mixed-effects model representation for the functional scale measurement yij on patient
i at time tij :
yij = (β0 + b0i)+(µ(xi) + b1i) tij+ǫij , [b0i, b1i]
′∼N (0,Λ) and ǫij∼N
(
0, σ2
)
, all stoch. independent.
(8)
18
The DR parameter in this case is the linear slope of disease progression µ(x). If µ(x) is represented by
a linear function of dose x, the model in (8) is a linear mixed-effects (LME) model, else it becomes a
nonlinear mixed-effects (NLME) model. In particular, under the ANOVA parametrization discussed
in Section 2.1, µ(xi) = µi, (8) is an LME model with different slopes for each dose.
The research interest in this study focuses on the treatment effect on the linear progression slope.
At t = 1 year this is numerically equal to the average change from baseline, and thus easily
interpretable. At the planning stage of the trial, the following assumptions were agreed with the
clinical team for the purpose of design:
• Natural disease progression slope = -5 points per year.
• Placebo effect = 0 (i.e., no change in natural progression).
• Maximum improvement over placebo within dose range = 2 points increase in slope over
placebo.
• Target (clinically meaningful) effect = 1.4 points increase in slope over placebo.
Guesstimates for the variance-covariance parameters were obtained from historical data: var (b0i) =
100, var (b1i) = 9 corr (b0i, b1i) = −0.5, and var (ǫij) = 9. Under these assumptions, it is easy to see
that the covariance matrix of the ANOVA-type estimate µ̂ of the slopes µ = (µ1mg, µ3mg, µ10mg, µ30mg)
′
is compound-symmetric. With these concrete guesstimates, the diagonal element is 0.1451 and the
off-diagonal element 0.0092.
From discussions with the clinical team, the four candidate models displayed in Figure 4 were
identified:
• Emax model with 90% of the maximum effect at 10 mg, corresponding to an ED50 = 1.11
• Quadratic model with maximum effect at 23 mg, corresponding to standardized model pa-
rameter δ = −0.022
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Figure 4: Candidate models for neurodenerative disease example.
• Exponential model with 30% of the maximum effect occurring at 20 mg, corresponding to a
standardized model parameter δ = 8.867
• Linear model
For confidentiality reasons, the data from the actual trial cannot be used here, so we utilize a
simulated dataset with characteristics similar to the original data with an Emax DR profile imposed
on the linear slopes µ(x). Figure 5 shows the simulated data per dose, which is available in the
DoseFinding package, in the neurodeg data set.
In what follows we illustrate the individual steps of MCPMod along with its implementation in
DoseFinding package (version 0.9-6).
The µ̂ vector is estimated via an LME fit of data, which can be done, for example, using the lme
function in the nlme R package, as illustrated below.
data(neurodeg)
head(neurodeg, n=3)
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Figure 5: Simulated data for neurodegenerative disease example. Gray lines correspond to individual
patient profiles, black line to loess smoother.
> resp id dose time
> 1 191.7016 1 0 0
> 2 178.3995 1 0 3
> 3 167.3385 1 0 6
fm <- lme(resp ~ as.factor(dose):time, neurodeg, ~time|id)
muH <- fixef(fm)[-1] # extract estimates
covH <- vcov(fm)[-1,-1]
The estimated slopes are µ̂ = (−5.099,−4.581,−3.220,−2.879,−3.520)′ with corresponding esti-
mated variance-covariance matrix with compound symmetry structure with diagonal elements 0.149
and off-diagonal elements 0.0094.
The optimal contrasts corresponding to the candidate models are calculated using the formula
in (3), with S given by the estimated variance-covariance matrix of µ̂. The DoseFinding package
includes the function optContr to calculate optimal contrasts based on (3) as follows.
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doses <- c(0, 1, 3, 10, 30)
mod <- Mods(emax = 1.11, quadratic=-0.022, exponential = 8.867, linear = NULL,
doses = doses) # definition of candidate shapes
contMat <- optContr(mod, S=covH) # calculate optimal contrasts
The MCTtest function in the DoseFinding package implements the optimal model contrast tests
for µ̂ based on the multiple comparison approach described in Section 2.2.
MCTtest(doses, muH, S=covH, type = "general", critV = T, contMat=contMat)
> . . .
> Multiple Contrast Test:
> t-Stat adj-p
> emax 4.561 <0.001
> quadratic 3.680 <0.001
> linear 2.274 0.0249
> exponential 1.277 0.1818
>
> Critical value: 2.275 (alpha = 0.025, one-sided)
The Emax, quadratic and linear model contrasts are all significant, but the exponential model failed
to reach significance. Therefore, the significance of a dose-response signal is established and we can
move forward to estimating the dose-response profile and the target dose.
Two approaches can be used for model fitting in this example: the two-stage GLS non-linear dose-
response fitting method described in Section 3, or mixed-effects modeling (linear and nonlinear)
incorporating a parametric dose response model for the progression slope µ(x). We consider first the
two-stage GLS method, which is implemented in the fitMod function in DoseFinding, illustrated
in the call below for the Emax model.
fitMod(doses, muH, S=covH, model="emax", type = "general", bnds=c(0.1, 10))
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> Dose Response Model
>
> Model: emax
> Fit-type: general
>
> Coefficients dose-response model
> e0 eMax ed50
> -5.181 2.180 1.187
The gAIC values (as discussed in Section 3.1) corresponding to the fits for the Emax, quadratic,
and linear models are, respectively: 10.66, 11.07 and 24.22, indicating the better adequacy of the
Emax model. Note that the DoseFinding package also includes an MCPMod function that performs
MCTtest, model selection and model fitting in one step.
The mixed-effects model fit approach in this case is illustrated below for the Emax model using the
nlme function
nlme(resp ~ b0 + (e0 + eM * dose/(ed50 + dose))*time, neurodeg,
fixed = b0 + e0 + eM + ed50 ~ 1, random = b0 + e0 ~ 1 | id,
start = c(200, -4.6, 1.6, 3.2))
...
Fixed: b0 + e0 + eM + ed50 ~ 1
b0 e0 eM ed50
200.451303 -5.178739 2.181037 1.198791
The estimated fixed effects from the NLME model are quite close to the estimates obtained via the
GLS two-stage method. The AIC values corresponding to the Emax, quadratic and linear models
under the mixed-effects model fit are, respectively: 8352.60, 8353.10 and 8365.79 confirming the
Emax as the best fitting model. It is intriguing to see how similar the differences in AIC between
the different models are to the differences in gAIC values.
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Estimates for the target dose, that is, the smallest dose producing an effect greater than or equal to
the target value of 1.4, can be obtained with either of the model fitting approaches. The resulting
estimated target doses are 2.13 under the two-stage GLS method and 2.15 under the NLME model.
Alternatively, model averaging methods could have been used to estimate the target dose and the
dose-response profile.
4.2 Binary and placebo-adjusted data
In this section we will go through two concrete examples on how to use the DoseFinding R pack-
age to apply MCPMod to binary data and placebo-adjusted normal data. Only the required R
commands are given here, but not the output.
4.2.1 Binary endpoint
This example is based on trial NCT00712725 from clinicaltrials.gov. This was a randomized,
placebo-controlled dose response trial for the treatment of acute migraine, with a total of 7 active
doses ranging between 2.5mg and 200mg and placebo. The primary endpoint was “being pain free
at 2 hours postdose”, i.e., a binary endpoint. The analysis presented here is a post-hoc analysis.
As a reasonable set of candidate models and contrasts, we select 4 different shapes of the sigmoid
Emax model f(x, θ) = E0 + Emaxx
h/(xh + EDh50), which cover a very wide range of monotonic
shapes and a quadratic model to safeguard against the possibility of a unimodal dose response
relationship. The Mods function is used for that, and one can also plot the candidate shapes.
doses <- c(0,2.5,5,10,20,50,100,200)
models <- Mods(sigEmax = rbind(c(2.5, 1),c(10,1),c(50, 3),c(100,2)),
quadratic = -1/250, doses=doses)
plot(models)
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The first stage of the two-step MCPMod approach consists of fitting a model with ANOVA-type
parametrization to the data to obtain estimates µ̂ and its asymptotic covariance matrix S. The
logistic regression model is used here, which means that the candidate models are formulated on
the logit scale (other scales could be used). The ANOVA logistic regression model can be fitted as
follows.
## data from NCT00712725 study
dosesFact <- as.factor(doses) ## treat dose as categorical variable
N <- c(133, 32, 44, 63, 63, 65, 59, 58)
## % of patients painfree at 2h post-dose
RespRate <- c(13,4,5,16,12,14,14,21)/N
## fit logistic regression (without intercept)
logfit <- glm(RespRate~dosesFact-1, family = binomial, weights = N)
muHat <- coef(logfit)
S <- vcov(logfit)
Now all subsequent inference only depends on muHat and S obtained from the logistic regression.
The multiple contrast test from 2.2 using optimal trend contrasts can be produced as follows
MCTtest(doses, muHat, S=S, models = models, type = "general")
All contrasts are significant. The modeling step can now be performed using the fitMod function.
Here for illustration we fit the sigmoid Emax model and the quadratic model.
modSE <- fitMod(doses, muHat, S=S, model = "emax", type="general")
modQuad <- fitMod(doses, muHat, S=S, model = "quadratic", type = "general")
gAIC(modSE);gAIC(modQuad)
A comparison of the gAIC values reveals that the sigmoid Emax model provides a better fit than
the quadratic model.
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Above we performed the different steps of the MCPMod procedure separately. One could alterna-
tively have used
MCPMod(doses, muHat, S=S, models=models, type = "general", Delta = 0.2)
directly.
4.2.2 Fitting on placebo-adjusted scale
For this example we use the IBScovars data set from the DoseFinding package, taken from [3]. The
data are part of a dose ranging trial on a compound for the treatment of irritable bowel syndrome
with four active doses 1, 2, 3, 4 equally distributed in the dose range [0, 4] and placebo. The primary
endpoint was a baseline adjusted abdominal pain score with larger values corresponding to a better
treatment effect. In total 369 patients completed the study, with nearly balanced allocation across
the doses.
The endpoint is assumed to be normally distributed and it is of interest to adjust for the additive
covariate gender. While the DoseFinding package can deal with this situation exactly, here we
illustrate using the placebo-adjusted (effect) estimates. Note that, in the case of time-to-event data,
one would proceed similarly. Here we only illustrate fitting an emax model, using the MCTtest and
MCPMod functions is analogous to the calls in Section 4.2.1, but using the additional argument
placAdj = TRUE. We plot the fitted model together with confidence intervals for the model fit and
the ANOVA type effect estimates.
data(IBScovars)
anovaMod <- lm(resp~factor(dose)+gender, data=IBScovars)
drFit <- coef(anovaMod)[2:5] # placebo adjusted (=effect) estimates at doses
S <- vcov(anovaMod)[2:5,2:5] # estimated covariance
dose <- sort(unique(IBScovars$dose))[-1] # vector of active doses
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## now fit an emax model to these estimates
gfit <- fitMod(dose, drFit, S=S, model = "emax", placAdj = TRUE,
type = "general", bnds = c(0.01, 2))
plot(gfit, CI = TRUE, plotData = "meansCI")
5 Conclusions
The extended MCPMod methodology, together with its corresponding software implementation in
the DoseFinding package in R, greatly broaden the scope of application of the original MCPMod
approach. Most type of endpoints, and associated model-based analyses, utilized in dose finding
studies can be handled in the context of the extended approach.
Further extensions of the approach discussed here are possible and of interest in practice. An
increasing number of indications and drugs require regimen selection, in addition to the more
traditional dose selection. Different approaches can be considered in the context of MCPMod, or
its extension, discussed here. One could focus on estimating the exposure-response relationship,
for example, combing dose and regimen into one model covariate. The much larger number of
exposure values, compared to dose levels, could pose a problem for the derivation of optimal model
contrasts and for the MCP step, more generally. Dose-time response modeling in the context of
model uncertainty provide another venue for extending MCPMod. Further research is needed in
those topics.
Model-based dose finding methods, such as the extended MCPMod, provide better understanding
of the dose-response relationship, generally translating into more accurate dose selection for con-
firmatory trials. Realizing the full potential that these methods have to offer, however, requires
changes in the way Phase II studies are traditionally designed. By and large, dose finding studies
are planned as mini Phase III trials, using hypothesis tests to select the dose, or doses, to bring
forward to the confirmatory stage. Relatively few doses (typically two active treatment arms and
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placebo) are used in such Phase II studies, making it hard to entertain any type of modeling. The
sample size derivation in this type of studies is based on power calculations for detecting at least one
dose significantly different from placebo. The resulting number of subjects is typically inadequate
for proper estimation of target doses (and dose response modeling). A discussion of a different
balance in resource allocation between Phases II and III, taking into account the overall probability
of program success, is long overdue. Utilization of larger number of doses (e.g., 4 or 5), coupled
with larger sample sizes, would go along way in enabling model-based methods to improve dose
selection in Phase II and, as a result, the probability of success in Phase III.
A Derivation of Optimal Contrasts
In this section the closed form solution for the optimal contrasts for the case of a general covariance
structure is derived. Optimality here refers to maximum power of the univariate contrast test, if a
specified mean vector µ (with corresponding positive definite covariance matrix S) is true, which
means that the non-centrality parameter
g(c,µ) =
c′µ√
c′Sc
,
needs to be maximized with respect to c, subject to c′1 = 0.
Writing C0 =
(
−1K−1...IK−1
)
, the constrained maximization problem is equivalent to the uncon-
strained maximization of (c
′
C0µ)
2
c′C0SC0
′
c
. This, however, is the solution to the generalized eigenvalue
problem
C0µµ
′C ′0x = λC0SC0
′x,
see e.g. [1], formula (2.66). As C0µµ
′C ′0 is of rank 1, it has only a single non-zero eigenvalue.
Thus, it is immediately clear that c = const · (C0SC ′0)−1C0µ, const 6= 0 is the only solution to the
generalized eigenvalue problem. We further note that c = const ·(C0SC ′0)−1C0µ = const ·S−1(µ−
µ′S−11
1′S−11
1). It is clear that the optimal solution is invariant with respect to addition or multiplication
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of any scalar constant to the vector µ, which is why one can also use the standardized mean vectors
µ0m instead of µ, which then gives the result in formula (3).
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B Placebo-adjusted dose response modeling
In a few cases one would like to perform MCPMod on placebo-adjusted estimates, for example when
there are (additive) covariates in the model, or when using a Cox PH model (where one can only
obtain control-adjusted estimates). In what follows we will first demonstrate the equality of test
statistics, and calculate optimal contrasts. Then
B.1 Test statistics and optimal contrasts
If we want to test a linear contrast of the responses per dose group, it does not matter whether we
fit a placebo adjusted curve or include the placebo group as a response and then test contrasts to
placebo.
To see this, consider the ANOVA estimate
µ̂ ∼ N(µ,S) (9)
where the first component µ̂0 of the vector µ̂ corresponds to the placebo response. The test
contrasts can then be produced by multiplication of µ̂ with the (K − 1) × K contrast matrix
C0 =
(
−1K−1...IK−1
)
, where 1K−1 is a column vector of ones of size K − 1 and IK−1 the K − 1
dimensional identity matrix. We obtain the corresponding contrast
µ̂C ∼ N(µC ,SC) (10)
with µ̂C = C0µ̂, µC = C0µ and SC = C0SC0.
The contrast test statistic in model (9) is of the form
mC = max
c′µ̂√
c′Sc
subject to c′1K = 0, (11)
with c such that mC attains a maximum. In model (10), the restriction on c is already absorbed
in the matrix C0 and the test statistic takes the form
mP = max
d′C0µ√
d′C0SC
′
0d
, (12)
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where d is no longer a contrast and again d is chosen such that mP is at its maximum. Now, it
can be seen that c = C ′0d: Setting c = C
′
0d implies c
′1K = 0, as C01K = 0. Hence, mC ≥ mP .
On the other hand, if c′1K = 0, then there must be some d ∈ RK−1 such that c can be written as
c = C′0d, since the rows of the (K − 1)×K-matrix C0 provide a base of the (K − 1)-dimensional
hyperspace orthogonal to 1K in R
K . Consequently, mC ≤ mP . It follows that mC = mP and that
if d maximizes (12), then C′0d maximizes (11).
Specifically the optimal dopt can be calculated as dopt = S−1C µC , as the sum to 0 constraint is
removed.
B.2 Dose Response Model Fitting
In the two-stage generalized least squares fitting procedure one minimizes the criterion
(f(x, θ)− µ̂)′S−1(f(x, θ)− µ̂). (13)
When we only have µ̂C one would not fit a full dose response model θ0 + θ1f
0(x, θ0) but work with
a model without the intercept θ0. fC(x, θ) = θ1f(x, θ
0). The optimization criterion proposed for
placebo-adjusted is then
(fC(x, θ)− µ̂C)′S−1C (fC(x, θ)− µ̂C). (14)
When f 0(0, θ0) = 0 one can see that (13) and (14) are equal. This follows from the fact that (14)
is equal to
(C0(f(x, θ)− µ̂))′(C0SC ′0)−1(C0(f(x, θ)− µ̂)),
and because C ′0(C0SC
′
0)
−1C0 = S
−1 (which follows from multiplication from the left with C0S).
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C Proof of the result in section 3.1
Let θ0 denote the true value of the parameter θ and µ0 = f (x, θ0) where x is a known vector of
fixed values. Assume that the following conditions are satisfied:
(A1) There exists a symmetric, positive definite estimate S of the covariance matrix of µ̂ with
anS
P→ Σ for a positive nondecreasing sequence an converging to∞ as n→∞, and a positive
definite, symmetric matrix Σ ∈ Rd×d.
(A2) If N(0,Σ) denotes the multivariate normal distribution with mean 0 and covariance matrix
Σ, then an
1/2(µ̂ − µ0) d→ N(0,Σ), where d→ denotes convergence in distribution. As a
consequence of an → ∞, the estimate µ̂ is consistent, i.e., µ̂ P→ µ0 (see e.g. Serfling, 1980,
p.26).
(A3) The mapping Θ 7→ Rk, θ 7→ f (x, θ), with x ∈ Rk is a bijective function of θ which is twice
differentiable in an open region around θ0.
Under these assumptions θ̂ is a consistent estimator of θ, i.e., θ̂
P→ θ and √an(θ̂ − θ0) d→
N(0,B(θ0)
′M(θ0)B(θ0)), where M(θ) = F (θ)
′AΣAF (θ) and B(θ) = (F (θ)′AF (θ))−1.
Proof:
Let Ψ̂(θ) = (µ̂− f (x, θ))′An(µ̂− f (x, θ)) and Ψ(θ) = (µ− f (x, θ))′A(µ− f (x, θ)).
First we note that consistency of the estimator is easy to establish using standard theory for the
consistency of M-estimators. For example the three conditions in Theorem 5.7 from [39] are easy
to verify (A1)-(A3).
The proof of the distribution of
√
an(θ̂− θ0) d→ N(0,B(θ0)′M (θ0)B(θ0)) works along the lines of
[33, ch. 12.2.3], which we restate here with the modifications needed for our situation.
As θ̂ minimizes Ψ̂(θ), we havedΨ̂(θ̂)
dθ
= 0. Thus, by the mean value theorem, there is a θ˜ between
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θ0 and θ̂ such that
0 =
dΨ̂(θ0)
dθ
+
d2Ψ̂(θ˜)
dθdθ′
(θ0 − θ̂).
Hence
√
an(θ̂ − θ0) = √an(d
2Ψ̂(θ˜)
dθdθ′
)−1(
dΨ̂(θ0)
dθ
). (15)
We now show that (i)
√
an
dΨ̂(θ0)
dθ
is asymptotically normal, and that (ii)
(
d2Ψ̂(θ˜)
dθdθ′
)−1
converges in
probability to a non-singular matrix.
(i)
dΨ̂(θ)
dθ
= −2F (θ)An(µ̂− f (x, θ)),
where F (θ) is the d× k matrix of partial derivatives df(xi,θ)
dθh
. (i = 1, ..., k, h = 1, ..., d).
Since
√
an (µ̂− f(x, θ0)) d→ N(0,Σ),
√
an
dΨ̂(θ0)
dθ
= −2√anF (θ0)An (µ̂− f(x, θ0)) d→ N(0, 4F (θ0)AΣA′F (θ0)′)
.
(ii) Differentiate the second term twice to get
d2Ψ̂(θ˜)
dθdθ′
= −2(U − F (θ˜)AnF (θ˜)′),
where U is the d× d matrix with h-th column given by
d2f(x, θ)
dθhdθ
′
An(µ̂− f (x, θ˜)).
Now µ̂
P→ f(x, θ0) and θ̂ P→ θ˜ P→ θ0, so all entries of U converge to 0. In total we get
d2Ψ̂(θ˜)
dθdθ′
P→ 2F (θ0)AF (θ0)′
DefiningM(θ) = F (θ)AΣA′F (θ)′ and B(θ) = (F (θ)AF (θ)′)−1 and inserting the results from (i)
and (ii) into (15), one obtains that the asymptotic distribution of
√
an(θ̂−θ0) isN(0,B(θ0)′M(θ0)B(θ0)).

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Figure 6: Time-To-Event endpoint
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